Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / bristol myers squibb strengthens oncology portfolio mwn benzinga

MRTX - Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal | Benzinga

Mirati Therapeutics Inc.

Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ: MRTX) for $58.00 per share in cash, for a total equity value of $4.8 billion. 

Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, representing an additional $1.0 billion of value opportunity. 

Also Read: Amgen's Adcomm Meeting Paves ...

Full story available on Benzinga.com
Stock Information
Company Name: Mirati Therapeutics Inc.
Stock Symbol: MRTX
Market: NASDAQ
Website: mirati.com
Menu
MRTX MRTX Quote MRTX Short MRTX News MRTX Articles MRTX Message Board
Get MRTX Alerts

News, Short Squeeze, Breakout and More Instantly...